SCHEDULE: Biotechnology Value Fund Increases Annexon Stake

Biotechnology Value Fund and its affiliates have disclosed a 5.4% beneficial ownership stake in Annexon, Inc. following the exercise of pre-funded warrants.

Summary

• The reporting group, led by Mark N. Lampert and BVF Partners L.P., now beneficially owns 8,698,173 shares of Annexon, Inc. common stock.
• This ownership represents approximately 5.4% of the company's outstanding shares.
• The increase in holdings resulted from the exercise of pre-funded warrants on March 27, 2026.
• The reporting persons certify that these shares were not acquired for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, reflecting continued institutional support for the company's equity.

Positives

• The investment firm maintains a significant position, signaling long-term confidence in the issuer's prospects.
• The exercise of pre-funded warrants indicates active management of the investment position.

Negatives

• None identified in this ownership disclosure.

Risks

• The investment is subject to market volatility inherent in the biotechnology sector.
• The reporting persons' ability to influence corporate governance is limited by their passive investment certification.

Future Outlook

The reporting persons have certified that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that institutional accumulation in mid-cap biotech firms often precedes or follows significant clinical trial milestones or capital structure adjustments, such as the warrant exercises noted here.

Comparison to Industry Standards

• The filing follows standard SEC Schedule 13G reporting requirements for institutional investors exceeding the 5% ownership threshold.
• The use of pre-funded warrants is a common financing mechanism in the biotechnology sector to provide capital while deferring immediate dilution.

Stakeholder Impact

• Shareholders may view the increased institutional stake as a vote of confidence in the company's long-term strategy.

Next Steps

• Continued monitoring of future 13G or 13D filings for changes in ownership status.

Key Dates

Keywords

Annexon, BVF Partners, Schedule 13G, Biotechnology, Institutional Ownership, Mark N. Lampert